Literature DB >> 31226541

Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib.

Samuel B Tomlinson1, Stephen Sandwell2, Sally T Chuang3, Mahlon D Johnson4, G Edward Vates2, Patrick M Reagan5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31226541     DOI： 10.1016/j.leukres.2019.05.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  3 in total

1.  Central nervous system relapse in a pediatric anaplastic large cell lymphoma patient with CLTC/ALK translocation treated with alectinib: A case report.

Authors:  Jing Yang; Jun Li; Wei-Yue Gu; Ling Jin; Yan-Long Duan; Shuang Huang; Meng Zhang; Xi-Si Wang; Yi Liu; Chun-Ju Zhou; Chao Gao; Hu-Yong Zheng; Yong-Hong Zhang
Journal:  World J Clin Cases       Date:  2020-05-06       Impact factor: 1.337

2.  Alectinib Monotherapy in Isolated Central Nervous System Relapse of ALK-Positive Anaplastic Large Cell Lymphoma.

Authors:  Julian Verran; Vidya Mathavan
Journal:  Case Rep Hematol       Date:  2022-02-03

3.  Central nervous system relapse in a child with anaplastic large cell lymphoma: potential for new therapeutic strategies.

Authors:  Enass H Raffa; Helen M Branson; Bo Ngan; Sarah Alexander; Oussama Abla
Journal:  Cancer Rep (Hoboken)       Date:  2021-04-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.